Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.

about

Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells

P2860

Q58790921-A295D474-75C1-4617-8DC8-8F487FEFBD58

P2860

Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.

Item

http://www.wikidata.org/entity/Q51752158

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@en

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@nl

type

Item

label

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@en

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@nl

prefLabel

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@en

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@nl

P1476

Alisertib: a review of pharmac ...... malignancies and solid tumors.

@en

P2093

Ashley Huddleston

http://www.w3.org/2001/XMLSchema#string

Susanne Liewer

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

Aurora kinases as targets in drug-resistant neuroblastoma cells

MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.

P304

105-112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/13543784.2018.1417382

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29260599

http://www.w3.org/2001/XMLSchema#string

Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.

about

P2860

P2860

Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698